Drugs / GRF6019
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03765762 | Jan → Dec 2019 | Alzheimer disease | Alkahest, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03520998 | Apr 2018 → May 2019 | Alzheimer disease | Alkahest, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-28 | Grifols Therapeutics LLC | Results Alkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease grifols.com ↗
The trial met its primary endpoint, demonstrating that both dose levels were safe and well tolerated, with no clear difference in adverse events between the 100 and the 250 milliliter dose arms. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-28 | Grifols Therapeutics LLC | Alkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease grifols.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRF6019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03765762 ↗ |
| Modality | Protein / enzyme biologic | “GRF6019, a plasma-derived product” NCT03520998 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT03520998 ↗ |